doi:10.1007/s40268-013-0005-9 Liu L, Shi H, Xie M, Sun Y, Nahata MC
The slower titration schedule is also designed to improve tolerability and reduce the incidence of side effects as patients adjust to the medication
Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM
Reduced thirst + appetite: You may simply drink less water throughout the day without realizing it
Studies show that GLP-1 analogs as well as LFD affect visceral hypersensitivity (40, 41)
Semaglutide the original ~14.9% average body-weight reduction at 52 weeks Targets GLP-1 (one pathway) Weekly injection Best for: first-timers, or anyone sensitive to side effects Tirzepatide the upgrade ~22.1% average body-weight reduction at 52 weeks Targets GLP-1 + GIP (two pathways) Weekly injection Best for: plateaued on semaglutide, or want stronger results Retatrutide the newest ~25.9% average body-weight reduction at 52 weeks Targets GLP-1 + GIP + glucagon (three pathways) Weekly injection Best for: want the newest science, comfortable with a compounded option Semaglutide: the original Semaglutide is a GLP-1 receptor agonist
